Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Racing is the CEO's passion and hobby. The only reason BBDA exists is to fund this obsession with other people's money. He's not interested in any other marketing because it doesn't get him to the racetrack.
A majority of SOX relates to the relationship between auditors and the companies which they audit, as well as what must be inclduded in the notes to the financials statements. Obviously this doesn't impact a non-audited, non-SEC reporting pinksheet stock.
Yes, it did increase penalties on management for mistating their financials, but unfortunately the SEC doesn't have the staff or the time to review every hunk of junk pinksheet company out there.
How much more evidence do people need to understand that BBDA is solely a shell company setup for the purpose of funnelling money to the privately owned companies (and the CEO's hobbies)? It owns no patents, products, or anything else of value whatsoever.
Here are a few for you.
2009:
www.bloomberg.com/apps/news?pid=newsarchive&sid=axRntQx5Mrgo
When the end of Q-1 draws near and the revenues are received, BeBevCo will then start an equal to or greater stock buyback and retire shares," said CEO Brian Weber. "It is absolutely not our intention to run our share structure to the abyss and do a reverse split.
www.bloomberg.com/apps/news?pid=newsarchive&sid=a_XLYhMRTY4Q
Trying to avoid reverse splits by any means possible and staying true to our goals of category dominance over the next 6 months is our primary focus, as the receivables increase we will start a systematic share buyback as the months go on
www.investorpoint.com/news/BUYBACK1/46138315/
With the money we expect to raise in Europe in addition to our revenues, we expect to start the process of retiring more stock and a soft stock buyback in early 2012
And...the balance sheet still doesn't balance and I have yet to figure exactly what they think a statement of cash flows is supposed to show because the garbage in this report definitely isn't one.
I provided a link to the Wyoming SOS site which clearly shows that the entity was formed on 3/6/2013 by the same individual who formed both DLR Associates and Bebevco NY. In case you're too lazy to find the link here it is.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=177031181019240149007194227043002244007227131190
Not sure what other proof you need.
Did you miss the fact that this new marketing group was created by the CEO last month. This is not bringing in an established marketing company to help expand sales, it's a shell game.
40% is owned now by BBDA. The other 60% is undoubtedly owned by the person who formed the corporation, Mr. Brian Weber and/or Daisy Ramirez.
They PRd it as if it was an acquisition of a non-related established marketing company when in fact it's a newly formed shell already owned by the CEO. This is simply another attempt to pump up the PPS and further convolute the corporate structure, just as Olaf stated.
Indeed.
The Kudzu Agency appears to be a staffing and recruiting agency with one employee. Now they're supposedly and "Branding and Modelling Agency". My guess is that the Kudzu agency's director is a friend of the family.
Oh wait...here they are:
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=177031181019240149007194227043002244007227131190
Formed way back in March of 2013 by Curtis Sweltz, who also happens to be the organizer of the wonderfully profitable Bebida Beverage Company of NY, LLC.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=071060168050095068240100170188211073249238178003
And DLR Associates, Inc.
https://wyobiz.wy.gov/Business/FilingDetails.aspx?eFNum=035189245023187196181203115109244087187252163071
He's diluting. There's no reason to ask him why because there is no other purpose, regardless of what type of positive spin you might want to apply.
There is only one reason why a company gags their TA, and that is to hide dilution. There is absolutely no other purpose.
The fact of the matter is that none of these companies are moving much product because there's very limited demand for their niche products. Retailers like Walmart will give them a trial run, realize they don't sell, and dump them.
Your quotes show revenue multiples at 4.1X and yet you used 10X in your valuation. The complete sentence that you quoted below stated:
As a multiple of acquisition price, revenue multiples averaged 4.1 in 2010 compared with 3.4 in 2009, 3.5 in 2008, and 4.2 in 2007.
Just for the sake of accuracy, Earnings are not equal to Revenue. PE ratio is not applicable to a company with negative earnings.
It's a share selling scam, nothing more, nothing less.
Maybe somebody up there finally realized that the balance sheet doesn't...ummm...balance?
Not really since I'm not going to do anything with the information regardless. Also, it's more than likely false or misleading. Anyways, like you said I'm not really serving any purpose by pointing out the questionable nature of birdie talk so I'll just ignore those posts going forward.
Not worried at all. Insider games with pinksheets happens to be something that I don't like because when they're happening it's people like yourself and other common shareholders that get screwed in the end. GL.
He claims to have never sold a share and has spent months whining and complaining about management and his losses. Now all of a sudden he's full of information supposedly not yet available to the public. Portugal or not I'm sure the SEC would be interested in who was feeding him the information on which he was basing his trading decisions.
I have in no way read all of the recent studies regarding PEMF, but as far as I can tell BIEL is the only one arguing for heat as the mechanism of action. Read the comments submitted by the other PEMF companies posted on Regulations.gov, for example.
Ivivi:
Ivivi Health Sciences has dedicated considerable resources to elucidate the mechanism of action
of its signals. Studies have been carried out at the molecular, cellular, animal and human levels which
have led to the understanding that Ivivi devices act, not via heat, but in a signaling capacity which can
modulate the biological response to physical and chemical insult. As will unfold below, these studies
have significantly advanced knowledge in this area and will help FDA address safety and effectiveness
concerns.
Or it could simply be that BIEL doesn't understand what the classification actually means. BIEL describes it as a "non-thermal" category in their FDA update when in fact the official description of the ILX category is "diathermy, shortwave, for use other than applying therapeutic deep heat". Nowhere in the official description does it mention non-thermal, simply that the purpose of the device is for something other than deep heat of the tissue. The FDA has never claimed that the devices don't produce heat, just that wasn't the purpose of the devices, so we're back again to the mechanism of action for BIEL's products.
Given how BIEL has historically marketed and described the device the ILX category is absolutely the right place to put it, IMO. They've changed their tune, of course, but they weren't putting up much of a fight when they got their initial 510k approval as an ILX device.
Sec. 890.5290 Shortwave diathermy.
(a)Shortwave diathermy for use in applying therapeutic deep heat for selected medical conditions --(1)Identification. A shortwave diathermy for use in applying therapeutic deep heat for selected medical conditions is a device that applies to specific areas of the body electromagnetic energy in the radio frequency bands of 13 megahertz to 27.12 megahertz and that is intended to generate deep heat within body tissues for the treatment of selected medical conditions such as relief of pain, muscle spasms, and joint contractures, but not for the treatment of malignancies.
(2)Classification. Class II (performance standards).
(b)Shortwave diathermy for all other uses --(1)Identification. A shortwave diathermy for all other uses except for the treatment of malignancies is a device that applies to the body electromagnetic energy in the radio frequency bands of 13 megahertz to 27.12 megahertz and that is intended for the treatment of medical conditions by means other than the generation of deep heat within body tissues as described in paragraph (a) of this section.
(2)Classification. Class III (premarket approval).
(c)Date PMA or notice of completion of a PDP is required. No effective date has been established of the requirement for premarket approval for the device described in paragraph (b)(1). See 890.3.
Interesting discussion regardless. Nothing for it but to wait and see.
Right, I understand that. I think the problem is exacerbated by BIEL's complete 180 degree flip on the subject of whether or not the healing effects are from heat or the magnetic field itself. In the patent application they state there are benefits not related to heat, and yet on their website under the FDA status it states:
It is our assertion that over 30 years of research has produced no convincing evidence of any non-thermal effects with RF therapy.
An interesting line from the patent application:
Therapeutic value may be achieved by applying an electromagnetic field to injured bodily tissue. Application of a high-frequency electromagnetic field at a sufficiently low field strength so as not to produce tissue heating may result in a beneficial effect on healing of the tissue.
Presumably he's referring to the Form 15 they filed in April 2011 to deregister their shares with the SEC. He simply doesn't know the difference between deregister and delist.
Well, if you are correct and the majority of their new sales are from the newer, less expensive product then it's possible that a lot of that inventory could be the old $30 patches sitting in a storeroom somewhere that may eventually be written off. Impossible to know given the information available in the financials of course.
Think what you want, but it was pointed out that the increase in the frequency of PRs from BIEL was suspicious. And the rate just happened to jump on March 5 and included such gems as Malta, Malaysia and a paid-for personal award for the CEO. It has been good for traders who have capitalized on the PPS movements over the last couple of weeks, but insiders have probably benefited the most.
That's the income statement, not the balance sheet, but yes they did manage to cut some expenses so that's good.
Discussion is the purpose of this board is it not? Feel free to provide whatever counterpoints to my analysis you feel are relevant. Sure, revenue increased from Q3 to Q4, but Q4 is historically BIEL's strongest and it's down over 50% from Q4 2011, so I'm not sure I'd consider that positive. I've examined the balance sheet pretty thoroughly and can't find one thing I'd consider to be good, so please enlighten me.
You believe in the product and the potential, I get that, but from a financial standpoint it's a disaster.
Fair and balanced? I'm stating my opinion on the current condition of a pink sheet stock not anchoring the 5 O'clock news. I stated that I didn't think the growth of overseas sales would be fast enough to overcome the rising share count, so it seems as if we agree on how long it takes to generate new sales.
These financials are bad, no question and now they find themselves at the same place they were yesterday which is at the mercy of the FDA. One thing that is clear is that BIEL really needs to run better credit checks on their customers...20% of their revenue (38% of gross margin) was written off as bad debt expense. Considering 98% of their business is with 3 customers that's not good at all.
Anyways, this is the typical BIEL pattern. A flurry of PRs leading up the the release of the financials with what they hope will be a biggie (patent announcement) on the same day as the release. The point is to minimize the damage done by the financials and I really can't fault them for that even if it's predictable.
There is also a trend developing in their rate of dilution. If you ignore 2009 (where they really stuck it to the common shareholder with 1.2 billion shares), the pattern is pretty clear now.
2010 - 75 million shares issued (still fat with cash after 2009)
2011 - 400 million shares issued
2012 - 715 million shares issued
These of course correspond to the price of shares at issuance. If the average PPS for 2013 remains relatively flat to 2012 then you can expect another 700+ million shares to be issued (contingent on any additional debt conversion that might occur for Kelly Whelan shopping sprees) this year which would naturally necessitate an increase in the AS. If the PPS drops, then it's likely to be 1 billion+.
All this to say that, IMO, it is still FDA or bust for current shareholders as the rising OS count is severely limiting the rate off PPS increase due to organic sales growth outside of the U.S. There needs to be a shock event (FDA Approval) to run the PPS up high enough for current longs to realize a return on their investment. Traders will continue to have opportunities to play the swings of course, but if you're significantly down then the FDA is your potential saviour. In other words, business as usual.
Looks like typical buy the rumor, sell the news to me. Lots of buying in anticipation of the FDA meeting and then selling when the news of the delay got out. Good trading opportunities if you can time these events correctly.
Nope, I seriously don't even touch individual stocks anymore.
I don't trade pinks at all anymore. This is purely entertainment for me.
Markets are closed on Friday so we have very few trading days left prior to the FDA meeting.
Riding that FDA roller coaster, IMO. Good luck.
Looks like profit-taking. Many have doubled their money or better and it makes sense for them to lock in some gains.
I definitely agree that momentum is postitive right now. Personally I think a lot of the folks you mentioned have marked the FDA meeting on their calendars and are buying the rumor. We'll see what happens when we get closer to the meeting date.